Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 18(10): e0293466, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37878642

RESUMO

Gastric cancer (GC) is a prominent global health issue, as it ranks as the fifth most prevalent type of cancer and the fourth most significant cause of cancer-related mortality worldwide. Although H. pylori is known to play a role in the development of GC, genetic factors also play a role in its onset and progression. Recent studies have shown that genetic polymorphisms are strongly associated with the development of GC and that certain single nucleotide polymorphisms (SNPs) can be used as biomarkers for early diagnosis and prevention. Epigenetic disturbances, such as DNA methylation, are involved in the development of GC, and mutations in the DNA methyltransferase (DNMT) gene have been found to increase the risk of GC. However, previous findings on the association between DNMTs SNPs and GC risk have been inconsistent. In this study, an updated meta-analysis of three well-studied and controversial DNMTs polymorphic loci, DNMT1 rs16999593, DNMT3A rs1550117 and DNMT3B rs1569686, was performed to provide more reliable results. It was found that DNMT1 rs16999593 was not associated with GC, DNMT3A rs1550117 may have a positive association with GC risk, and DNMT3B rs1569686 may be a protective factor for GC. These findings may provide valuable information for early diagnosis and prevention of GC, but further studies are needed to confirm these results.


Assuntos
Predisposição Genética para Doença , Neoplasias Gástricas , Humanos , Genótipo , DNA Metiltransferase 3A , DNA (Citosina-5-)-Metiltransferases/genética , DNA (Citosina-5-)-Metiltransferase 1/genética , Polimorfismo de Nucleotídeo Único , Metilação de DNA , Neoplasias Gástricas/genética , Fatores de Proteção
2.
Oncol Rep ; 28(3): 977-84, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22710400

RESUMO

Cyclooxygenase-2 (Cox-2) is an inducible enzyme that converts arachidonic acid to prostaglandins, and it is hypothesized to induce carcinogenesis and metastasis in colorectal cancer. Our previous data also indicated that a higher expression level of Cox-2 was correlated with colorectal cancer metastasis. The Cox-2 protein was detected in the glandular cavity of colorectal cancer and the surrounding interstitial tissues. The usefulness of the Cox-2 gene as a gene therapy target and diagnostic marker remains unknown. In this study, a method using immuno-PCR and real-time PCR followed by supramolecular immunobead real-time PCR was established and used to detect the expression of Cox-2 in serum samples of nude mice with colorectal carcinoma. In addition, we established a Cox-2 gene stable knockdown colorectal cell line (SW480-EGFP-Cox-2 shRNA) using lentiviral vector-mediated RNA interference (RNAi) technology and established an imageable colorectal cancer metastasis mouse model. We found that the proliferation, invasion and tumorigenesis of SW480-EGFP-Cox-2 shRNA cells were attenuated compared with SW480 cells. In vivo experiments also demonstrated that angiogenesis in the Cox-2 knockdown colorectal cancer cells was decreased. The whole body optical imaging revealed that the SW480-EGFP-Cox-2 shRNA cells had an abrogated ability to develop metastases in the lymph nodes, lungs or liver in vivo. The improved immunobead PCR assay detected significantly lower Cox-2 protein levels in the serum samples of the SW480-EGFP-Cox-2 shRNA group compared with those of the SW480-EGFP-Cox-2-Ctrl shRNA group. In conclusion, our results indicated that the knockdown of Cox-2 expression suppressed the proliferation and invasion of colorectal cancer cells both in vitro and in vivo. This study also demonstrated that silencing Cox-2 in vivo reduced the metastastic potential of colorectal cancer. Thus, Cox-2 is a promising marker for the diagnosis of colorectal metastasis and a potential therapeutic target for colorectal cancer.


Assuntos
Biomarcadores Tumorais/sangue , Carcinoma/secundário , Neoplasias Colorretais/patologia , Ciclo-Oxigenase 2/sangue , Reação em Cadeia da Polimerase em Tempo Real/métodos , Animais , Biomarcadores Tumorais/genética , Carcinoma/sangue , Carcinoma/enzimologia , Linhagem Celular Tumoral , Proliferação de Células , Neoplasias Colorretais/sangue , Neoplasias Colorretais/enzimologia , Ciclo-Oxigenase 2/genética , Feminino , Técnicas de Silenciamento de Genes , Humanos , Imunoensaio , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Invasividade Neoplásica , Transplante de Neoplasias , Interferência de RNA , Imagem Corporal Total
3.
Nan Fang Yi Ke Da Xue Xue Bao ; 30(9): 2154-5, 2010 Sep.
Artigo em Chinês | MEDLINE | ID: mdl-20855277

RESUMO

OBJECTIVE: To investigate the acute toxicity and assess the median lethal dose (LD50) of matrine in Kunming mice. METHODS: Matrine at different doses were administered in Kunming mice via intraperitoneal injection, and the toxic reactions and LD50 of matrine was observed and determined. RESULTS: The acute toxicity test of matrine indicated that the tolerable dose of matrine was above 80 mg/kg in Kunming mice, and the LD50 was 157.13 mg/kg (95%CI, 88.08-280.31 mg/kg). Morphological observation revealed degenerative changes of the nerve cells in the brain tissue of the mice. CONCLUSION: The nervous system is the main target organ by the toxicity of matrine.


Assuntos
Alcaloides/toxicidade , Encéfalo/patologia , Quinolizinas/toxicidade , Animais , Encéfalo/efeitos dos fármacos , Feminino , Dose Letal Mediana , Masculino , Camundongos , Testes de Toxicidade Aguda , Matrinas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...